Y-mAbs Therapeutics (YMAB, Financial) has retained its "Outperform" rating as Oppenheimer analyst Jeff Jones maintains the company's status. The latest update on May 14, 2025, reaffirms the confidence in YMAB's future prospects despite some adjustments.
The price target for Y-mAbs Therapeutics (YMAB, Financial) has been lowered by Oppenheimer from a previous $21.00 to a new target of $20.00 USD. This adjustment reflects a 4.76% decrease in the price target. Despite this revision, the "Outperform" rating indicates continued positive expectations for the stock's performance relative to the market.
Investors in Y-mAbs Therapeutics (YMAB, Financial) should note the maintained rating amidst the downward adjustment in the price target. The decision by Oppenheimer highlights the nuanced view held by analysts, reflecting both optimistic and cautious elements in their valuation of the company's stock.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Y-mAbs Therapeutics Inc (YMAB, Financial) is $15.36 with a high estimate of $26.00 and a low estimate of $3.00. The average target implies an upside of 280.29% from the current price of $4.04. More detailed estimate data can be found on the Y-mAbs Therapeutics Inc (YMAB) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Y-mAbs Therapeutics Inc's (YMAB, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Y-mAbs Therapeutics Inc (YMAB, Financial) in one year is $11.67, suggesting a upside of 188.86% from the current price of $4.04. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Y-mAbs Therapeutics Inc (YMAB) Summary page.
